Healthpeak Properties (NYSE:DOC) Rating Increased to Buy at Deutsche Bank Aktiengesellschaft

Healthpeak Properties (NYSE:DOC) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a “hold” rating to a “buy” rating in a report released on Monday, MarketBeat Ratings reports. The firm currently has a $28.00 target price on the real estate investment trust’s stock, up from their previous target price of $20.00. Deutsche Bank Aktiengesellschaft’s price target would suggest a potential upside of 24.83% from the company’s current price.

Other research analysts also recently issued reports about the stock. Royal Bank of Canada boosted their price objective on shares of Healthpeak Properties from $22.00 to $25.00 and gave the company an “outperform” rating in a research report on Tuesday, July 30th. Scotiabank boosted their price objective on shares of Healthpeak Properties from $23.00 to $24.00 and gave the company a “sector outperform” rating in a research report on Monday, September 9th. Wells Fargo & Company restated an “equal weight” rating and set a $23.00 price objective (up from $22.00) on shares of Healthpeak Properties in a research report on Tuesday, October 1st. Evercore ISI boosted their price objective on shares of Healthpeak Properties from $25.00 to $26.00 and gave the company an “outperform” rating in a research report on Monday, September 16th. Finally, Wedbush boosted their target price on shares of Healthpeak Properties from $22.00 to $25.00 and gave the stock an “outperform” rating in a research note on Monday, July 29th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $22.62.

Healthpeak Properties Stock Up 1.1 %

NYSE DOC opened at $22.43 on Monday. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 0.91. Healthpeak Properties has a 1-year low of $15.24 and a 1-year high of $23.14. The company has a 50 day moving average of $22.19 and a 200-day moving average of $20.60. The company has a market cap of $15.79 billion, a price-to-earnings ratio of 64.09, a PEG ratio of 2.27 and a beta of 1.14.

Healthpeak Properties (NYSE:DOC) last released its quarterly earnings results on Thursday, July 25th. The real estate investment trust reported $0.21 earnings per share for the quarter, missing analysts’ consensus estimates of $0.44 by ($0.23). Healthpeak Properties had a net margin of 11.93% and a return on equity of 3.51%. The business had revenue of $695.50 million during the quarter, compared to analyst estimates of $665.11 million. During the same quarter in the previous year, the firm posted $0.45 earnings per share. The firm’s quarterly revenue was up 27.5% on a year-over-year basis. On average, equities research analysts expect that Healthpeak Properties will post 1.8 earnings per share for the current fiscal year.

Institutional Trading of Healthpeak Properties

Several institutional investors have recently modified their holdings of the business. International Assets Investment Management LLC bought a new stake in shares of Healthpeak Properties in the third quarter worth $62,310,000. Hartford Investment Management Co. bought a new stake in Healthpeak Properties during the third quarter valued at $1,004,000. Greenleaf Trust bought a new stake in Healthpeak Properties during the third quarter valued at $434,000. Commerzbank Aktiengesellschaft FI bought a new stake in Healthpeak Properties during the third quarter valued at $463,000. Finally, Lecap Asset Management Ltd. bought a new stake in Healthpeak Properties during the third quarter valued at $1,667,000. Institutional investors own 93.57% of the company’s stock.

About Healthpeak Properties

Healthpeak Properties, Inc is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates, and develops high-quality real estate for healthcare discovery and delivery.